Effect of late initiation of levodopa treatment in patients with long-standing parkinson's disease

Clinical Neuropharmacology

Volumn 26, Issue 1, 2003, Pages 24-27

  Djaldetti, Ruth ^a,b   Treves, Therese A ^a,b   Merims, Doron ^a,b   Sroka, Hava ^a,b   Melamed, Eldad ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Levodopa initiation; Parkinson's disease; Response fluctuations

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; HUMAN; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; CHRONIC DISEASE; HUMANS; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE; TIME FACTORS;

EID: 0037262286     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200301000-00006     Document Type: Article

References (17)

1. Spencer JP, Jenner A, Aruoma OL, et al. Intense oxidative DNA damage promoted by L-Dopa and its metabolites: implications for neurodegenerative diseases. FEBS Lett 1994;353:246-50.
2. Fahn S. Is levodopa toxic? Neurology 1996;47(suppl 3):S 184-95.
3. Melamed E, Offen D, Shirvan A, et al. Levodopa - an exotoxin or a therapeutic drug? J Neurol 2000;247(suppl 2):135-9.
4. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55:23-30.
5. Bressman SB, Shulman LM, Taner CM, et al. Long-term safety and efficacy of pramipexole in early Parkinson's disease. Neurology 1999;52:A261.
6. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with Parkinson's disease who are treated with ropinirole and levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91.
7. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-26.
8. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-75.
9. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;21:1364-71.
10. Diamond SG, Markham CH, Hoehn MM, et al. Multicenter study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
11. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival. A population-based study. Arch Neurol 2000;57:507-12.
12. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease - a community-based study. Brain 2000;123:2297-305.
13. De Jong GJ, Meerwaldt JD, Schmitz PI. Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 1987;22:4-7.
14. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-6.
15. Poewe WH, Lees AJ, Stem GM. Low-dose L-Dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986;36:1528-30.
16. Bedard PJ, Boucher R. Effect of D1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 1989;104:223-8.
17. Fahn S. Parkinson disease, the effect of levodopa and the ELLDOPA trial. Arch Neurol 1999;56:529-35.